pharmaphorum October 10, 2024
Our round-up of recent biotech financings features a strong first round for City Therapeutics, a new RNAi venture led by biotech doyen John Maraganore, and additional cash for Purespring, Judo Bio, GEMMABio, and Basecamp Research.
Cambridge, Massachusetts-based City Therapeutics emerged from the shadows with a $135 million Series A – led by ARCH Venture Partners – that will fund the development of a small interfering RNA (siRNA) drug discovery engine that the company thinks can deliver ‘new-generation’ drugs with improved potency and specificity, and which can be delivered to a wider range of tissue types.
Former Alnylam chief executive Maraganore, who will serve as executive chair of the new company, said his vision is that RNAi drugs will become “the...
Today's Sponsors
Today's Sponsor